Vaccination against human papillomavirus (HPV) is an important tool in the fight against this pathology throughout the world. In this line immunization program Canada has taken another step that could lead to a shift to an alternative, single-dose, gender-neutral approach to vaccinating and eliminating cervical cancer. This new model was published in CMAJ (Journal of the Canadian Medical Association).
“Our results are important political consequences in Canada and other similar high-income countries assessing whether to switch to single-dose HPV vaccination,” reflects Dr. Mark BrissonProfessor at Laval University, Quebec, and Director of the Laboratory of Mathematical Modeling and Health Economics of Infectious Diseases at the Laval University Research Center CHU de Québec.
“All single-dose vaccination scenarios, even the most pessimistic ones, assumed significantly more effective use of vaccine doses than two-dose vaccination.”
It is not surprising that countries around the world are exploring the possibility of abandoning the HPV vaccination strategy. from two doses to one one dose, as recommended in 2022 by the Strategic Advisory Group on Immunization of the World Health Organization (WHO), based on clinical trial data. The human papillomavirus can cause cervical cancer and other diseases.
In this direction, researchers from Ontario and Quebec have modeled various scenarios based on 1- and 2-dose approaches against HPV to support the recommendations of the Canadian National Advisory Committee on Immunization and the Quebec Committee on Immunization.
This Canadian approach uses vaccine doses more efficiently and is expected to help eradicate cervical cancer in Canada; although regular monitoring is recommended
The team found that one dose of a gender-neutral vaccination could prevent the same number of cases of cervical cancer as two doses if vaccine protection remained high at the age of peak sexual activity. “All single-dose vaccination scenarios, even the most pessimistic ones, assumed significantly more effective use of vaccine doses than two-dose vaccination; It was also predicted that all of these scenarios would lead to eliminating cancer
cervix in Canada between 2032 and 2040,” the authors write.This Canadian approach uses vaccine doses more efficiently and is expected to help eradicate cervical cancer in Canada; although it is recommended regular monitoring dose protection to identify signs of waning protection.
“The potential savings and programmatic flexibility of switching to single-dose vaccination could allow investment to improve vaccine acceptability across regions.”
“The Covid-19 pandemic has impacted HPV vaccination in Canada, particularly among vulnerable subgroups of the population. Potential saving What the move to single-dose vaccination will entail and its programmatic flexibility may allow investment in increasing vaccination coverage in regions where coverage is suboptimal and in subgroups with high HPV burden to mitigate the impact of the vaccination pandemic on programs and reduce inequalities. ” stated Dr. Chantal Sauvageau
public health specialist and infectious diseases consultant at the National Institute of Public Health of the Province of Quebec.